Jammu-based manufacturer of dental materials and equipment (restorative, endodontic, prosthodontic, preventive, orthodontic), sold via dealers and agents across 90+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 0 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 15 | 22 | 45 | 61 | 77 | 94 | 104 | 114 |
| Borrowings | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 4 | 7 | 6 | 6 | 6 | 7 | 8 | 8 |
| Total Liabilities | 21 | 31 | 64 | 79 | 95 | 113 | 123 | 134 |
| AssetsFixed Assets | 5 | 5 | 7 | 7 | 27 | 27 | 26 | 27 |
| CWIP | 0 | 2 | 5 | 17 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 1 | 1 | 2 | 5 | 7 | 9 |
| Other Assets | 16 | 23 | 52 | 53 | 66 | 81 | 90 | 98 |
| Total Assets | 21 | 31 | 64 | 79 | 95 | 113 | 123 | 134 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 3 | 5 | 9 | 7 | 10 | 11 | 15 | 16 |
| Cash from Investing | -1 | -1 | -2 | -4 | -12 | -2 | -2 | -2 |
| Cash from Financing | 0 | 0 | -1 | 23 | -1 | 0 | -1 | -1 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | 4 | 7 | 2 | -3 | 8 | 13 | 14 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (30.3×) and current (22.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10.9% growth and a 22× exit, ₹394 only delivers your return if you pay ₹285. The price is currently baking in 18% growth.
EPS grows 10.9%/yr for 5 years, then fades to 6% over 2, exits at 22×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.9% | 19.78 |
| FY28 | 10.9% | 21.94 |
| FY29 | 10.9% | 24.33 |
| FY30 | 10.9% | 26.98 |
| FY31 | 10.9% | 29.93 |
| FY32 | 8.4% ·fade | 32.46 |
| FY33 | 6.0% ·fade | 34.40 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.